cancer
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:162
Name cancer
Definition A disease of cellular proliferation that is malignant and primary, characterized by uncontrolled cellular proliferation, local cell invasion and metastasis.
Source DiseaseOntology.org
Alt Ids
Xrefs
ICDO:8000/3
SNOMEDCT_US_2023_03_01:269513004
Path disease disease of cellular proliferation cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02484053 Phase I Rituximab Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders Completed USA 0
NCT03543358 Phase II Rovalpituzumab Tesirine A Long-Term Study of Rovalpituzumab Tesirine Completed USA 0
NCT03768063 FDA approved Atezolizumab A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) Active, not recruiting USA | ROU | POL | ITA | HUN | GRC | FRA | ESP | DNK | DEU | CZE | BRA | BGR | BEL | AUS 9
NCT03844048 Phase III Venetoclax An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Active, not recruiting USA | TUR | SWE | POL | NZL | IRL | GRC | GBR | FRA | ESP | DNK | CAN | BEL | AUT | AUS 8
NCT03899155 FDA approved Nivolumab Pan Tumor Nivolumab Rollover Study Recruiting USA | TUR | SWE | ROU | POL | NZL | NOR | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG 11
NCT03912831 Phase I Cyclophosphamide + Fludarabine KITE-439 Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers Terminated USA 0
NCT03926143 Phase II Anetumab ravtansine A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies Terminated USA | POL | ITA | FRA 0
NCT04464226 Phase III Darolutamide Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer Active, not recruiting USA | TUR | SWE | SVK | ROU | POL | NLD | LVA | LTU | ITA | ISR | HUN | GBR | FRA | FIN | EST | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS | ARG 13